Gogas H - Search Results

1

COVID-19 in Patients with Melanoma: A Single-Institution Study.

Anastasopoulou A, Diamantopoulos PT, Kouzis P, Saridaki M, Sideris K, Samarkos M, Gogas H. Anastasopoulou A, et al. Among authors: gogas h. Cancers (Basel). 2023 Dec 24;16(1):96. doi: 10.3390/cancers16010096. Cancers (Basel). 2023. PMID: 38201522 Free PMC article.

2

Melanoma immunotherapy dominates the field.

Diamantopoulos P, Gogas H. Diamantopoulos P, et al. Among authors: gogas h. Ann Transl Med. 2016 Jul;4(14):269. doi: 10.21037/atm.2016.06.32. Ann Transl Med. 2016. PMID: 27563656 Free PMC article. Review.

3

Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.

Diamantopoulos PT, Gaggadi M, Kassi E, Benopoulou O, Anastasopoulou A, Gogas H. Diamantopoulos PT, et al. Among authors: gogas h. Melanoma Res. 2017 Aug;27(4):391-395. doi: 10.1097/CMR.0000000000000355. Melanoma Res. 2017. PMID: 28419059

4

Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.

Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H. Diamantopoulos PT, et al. Among authors: gogas h. J Immunother. 2017 Jul/Aug;40(6):221-223. doi: 10.1097/CJI.0000000000000172. J Immunother. 2017. PMID: 28498142

5

Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.

Anastasopoulou A, Papaxoinis G, Diamantopoulos P, Christofidou E, Benopoulou O, Stratigos A, Gogas H. Anastasopoulou A, et al. Among authors: gogas h. J Immunother. 2018 Apr;41(3):164-167. doi: 10.1097/CJI.0000000000000210. J Immunother. 2018. PMID: 29309291 Review.

6

Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.

Diamantopoulos PT, Stoungioti S, Anastasopoulou A, Papaxoinis G, Gogas H. Diamantopoulos PT, et al. Among authors: gogas h. Melanoma Res. 2018 Dec;28(6):648-651. doi: 10.1097/CMR.0000000000000505. Melanoma Res. 2018. PMID: 30169430

7

Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.

Bafaloukos D, Papaxoinis G, Linardou H, Diamantopoulos P, Laskarakis A, Anastasopoulou A, Sergentanis TN, Tarampikou A, Tsoutsos D, Gogas H. Bafaloukos D, et al. Among authors: gogas h. Melanoma Res. 2019 Aug;29(4):428-434. doi: 10.1097/CMR.0000000000000562. Melanoma Res. 2019. PMID: 30601377

8

Significance of survivin mRNA blood levels in patients with melanoma.

Samarkos M, Papaxoinis G, Athanasoula K, Benopoulou Ο, Bouros S, Anastasopoulou A, Diamantopoulos P, Gogas H, Mantzourani M. Samarkos M, et al. Among authors: gogas h. J BUON. 2018 Dec;23(7):96-103. J BUON. 2018. PMID: 30722117 Free article.

9

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B. Schilling B, et al. Among authors: gogas h. Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26. Cancer Immunol Immunother. 2019. PMID: 30806748 Free PMC article.

10

New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.

Diamantopoulos PT, Lakiotaki E, Kyriakakis G, Gogas H. Diamantopoulos PT, et al. Among authors: gogas h. Melanoma Res. 2020 Apr;30(2):206-208. doi: 10.1097/CMR.0000000000000627. Melanoma Res. 2020. PMID: 31157737

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

329 results

Search Page